این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Basic and Clinical Cancer Research، جلد ۱۰، شماره ۳، صفحات ۱۲-۲۱
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی High Insurance Coverage and Financial Support for Effective Cancer Drugs in I.R. Iran
چکیده انگلیسی مقاله Background: In recent years, financial coverage and availability of new and expensive cancer drugs have changed into one of the challenges of the health system, especially in low-income and middle-income countries,. We studied the availability ofanticancer drugs, insurance coverage and the financial burden of these drugs in Iran. Methods: In this cross-sectional descriptive study, first, we listed effective cancer drugs according to the World Health Organization’s Model List of Essential Medicinesand previous studies. Then, we evaluated financial burden of these drugs byusing the available data in Iran pharmaceutical Pharmacopoeia, the national pharmaceuticalsales statistics database (pharmaceutical Amarnameh), and inquiry of the insurance organizations, the availability, insurance coverage in Iran. Excel softwarewas used for data analysis. Results: All of the medicines incorporated into the latest version of the WHO Model List of Essential Medicines were available in Iran, and, except for Bendamustine and Anastrazole all medicines were covered by insurance. In addition, of the 19 drugs,those were not on the WHO Model List of Essential Medicines, there were sevendrugs in Iran, insurance covered that six drugs. The total Dollar sales of the studied cancer drugs amounted to US$350.85 million in 2015 and US$384.96 million in 2016. Conclusion: It seems that the status of access to effective cancer drugs in Iran is better than many low and middle-income countries. However, since the cost of cancerdrugs is rising, health policy makers inevitably need to prioritize cancer drugs by using the results of health technology assessment methods and provide patients withaccess to drugs that are cost-effective in order to the optimal allocation of limited resources and provide maximum access to cancer drugs throughout the country.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Alireza Darrudi
Master of Sciences Student in Health Economics, Health Management and Economics Department, Students Scientific Research Center, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran


| Rajabali Daroudi
Health Economics, Health Management and Economics Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
نشانی اینترنتی http://bccr.tums.ac.ir/index.php/bccrj/article/view/276
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/151/article-151-1354998.pdf
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات